NASDAQ:ARAY - Accuray Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 39.86 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.29 (-6.33%)
1 month | 3 months | 12 months
Get New Accuray Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARAY

Average Price Target: $6.00
▲ +39.86% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Accuray in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 39.86% upside from the last price of $4.29.


The current consensus among 2 investment analysts is to buy stock in Accuray. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/7/2021Northland SecuritiesInitiated CoverageOutperformN/A
8/14/2020BTIG ResearchReiterated RatingBuy$6.00High
6/21/2020Lake Street CapitalReiterated RatingBuy$10.00High
6/21/2020CowenReiterated RatingMarket Perform ➝ Average$8.00High
6/17/2020BTIG ResearchReiterated RatingBuy$6.00Medium
1/21/2020BTIG ResearchUpgradeNeutral ➝ Buy$9.50High
8/16/2019Royal Bank of CanadaSet Price TargetHold$4.00Low
4/24/2019BTIG ResearchReiterated RatingHoldHigh
11/1/2018CitigroupUpgradeSell ➝ Neutral$3.50 ➝ $3.90High
8/22/2018BTIG ResearchReiterated RatingHoldMedium
8/17/2018Jefferies Financial GroupReiterated RatingBuy$6.00Low
8/17/2018CitigroupLower Price TargetSell ➝ Sell$4.00 ➝ $3.50High
4/10/2018Royal Bank of CanadaSet Price TargetHold$6.00High
1/24/2018Royal Bank of CanadaSet Price TargetHold$6.00Medium
12/13/2017JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$6.00High
11/30/2017Lake Street CapitalInitiated CoverageBuy ➝ Buy$10.00High
10/27/2017CowenReiterated RatingBuy$9.00N/A
8/24/2017BTIG ResearchReiterated RatingHoldMedium
8/24/2017Royal Bank of CanadaReiterated RatingHold$5.00Low
8/23/2017Jefferies Financial GroupLower Price TargetBuy$7.00 ➝ $6.00Low
8/9/2017Jefferies Financial GroupReiterated RatingBuy$7.00Medium
6/30/2017Jefferies Financial GroupReiterated RatingBuy$7.00High
4/30/2017BTIG ResearchReiterated RatingHoldMedium
4/29/2017Jefferies Financial GroupReiterated RatingBuy$8.00 ➝ $7.00Low
3/21/2017AegisReiterated RatingBuyMedium
2/6/2017AegisInitiated CoverageBuy$7.00N/A
2/5/2017BTIG ResearchReiterated RatingHoldN/A
12/14/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$8.00 ➝ $6.00N/A
11/7/2016Jefferies Financial GroupReiterated RatingBuy$8.00N/A
9/27/2016Jefferies Financial GroupReiterated RatingBuy$8.00N/A
9/13/2016CowenInitiated CoverageOutperform$9.00N/A
8/18/2016Morgan StanleySet Price TargetHold$8.00N/A
(Data available from 6/21/2016 forward)
Accuray logo
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
Read More

Today's Range

Now: $4.29
Low: $4.29
High: $4.61

50 Day Range

MA: $4.65
Low: $4.24
High: $5.51

52 Week Range

Now: $4.29
Low: $1.96
High: $6.01


2,003,900 shs

Average Volume

863,873 shs

Market Capitalization

$400.09 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Accuray?

The following equities research analysts have issued stock ratings on Accuray in the last year: BTIG Research, Cowen Inc, Lake Street Capital, Northland Securities, and Zacks Investment Research.
View the latest analyst ratings for ARAY.

What is the current price target for Accuray?

3 Wall Street analysts have set twelve-month price targets for Accuray in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 86.5%. Lake Street Capital has the highest price target set, predicting ARAY will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $6.00 for Accuray in the next year.
View the latest price targets for ARAY.

What is the current consensus analyst rating for Accuray?

Accuray currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARAY will outperform the market and that investors should add to their positions of Accuray.
View the latest ratings for ARAY.

What other companies compete with Accuray?

How do I contact Accuray's investor relations team?

Accuray's physical mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider's listed phone number is 408-716-4600 and its investor relations email address is [email protected] The official website for Accuray is